Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT versus BETAMETHASONE DIPROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT versus BETAMETHASONE DIPROPIONATE.
ARISTOCORT vs BETAMETHASONE DIPROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; modulates gene expression and immune cell activity.
Betamethasone dipropionate is a glucocorticoid receptor agonist that binds to cytosolic glucocorticoid receptors, leading to modulation of gene transcription. It suppresses pro-inflammatory cytokines (e.g., IL-1, IL-2, TNF-α), inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes mast cells.
Intramuscular: 40-80 mg every 2-4 weeks; Intra-articular: 5-40 mg depending on joint size; Intralesional: 2.5-25 mg; Oral: 4-12 mg/day divided every 6-12 hours.
Apply topically as 0.05% cream, ointment, or lotion to affected area once or twice daily. Maximum: 45 g/week.
None Documented
None Documented
Plasma: 1-2 hours (triamcinolone); tissue half-life 18-36 hours due to receptor binding and slow release from tissues.
Terminal elimination half-life: 6-8 hours (parenteral); clinically, duration of adrenal suppression may extend beyond this.
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal elimination minor.
Renal, ~75% as conjugated metabolites; biliary/fecal, ~25%.
Category C
Category D/X
Corticosteroid
Corticosteroid